Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA.
about
Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kgSafety and efficacy of enzyme replacement therapy in the nephropathy of Fabry diseaseCharacterization of gana-1, a Caenorhabditis elegans gene encoding a single ortholog of vertebrate alpha-galactosidase and alpha-N-acetylgalactosaminidaseHuman Alpha Galactosidases Transiently Produced in Nicotiana benthamiana Leaves: New Insights in Substrate Specificities with Relevance for Fabry DiseaseUpdate on role of agalsidase alfa in management of Fabry disease.Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies.Biochemistry of glycosphingolipid storage disorders: implications for therapeutic interventionElevated globotriaosylsphingosine is a hallmark of Fabry disease.Agalsidase benefits renal histology in young patients with Fabry disease.Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis.Cost-effectiveness of enzyme replacement therapy for Fabry diseaseNovel therapeutic targets for the treatment of Fabry disease.Genetics of stroke: a review of recent advances.Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry DiseaseFabry disease, enzyme replacement therapy and the significance of antibody responses.Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease.Replacement of alpha-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients.Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.α-galactosidase A1.1 can functionally complement human α-galactosidase A deficiency associated with Fabry disease
P2860
Q21004071-D2544673-D2FA-4513-AB19-4A61766D474FQ24650910-0BDA57F9-1C7B-47A4-9DF7-26EB6BC30096Q24804185-42219249-D3F6-4140-8F56-8A751B28DD1BQ33819347-055C0B0A-8A1D-4A4C-BD85-21F497865869Q34883178-17D4A906-A712-4770-BDB0-101783996BCDQ35028532-2292055C-386C-4F98-82D9-61248432BCDEQ35153233-4F8D39F4-7AE3-46C1-A32E-F3446BDC0016Q36498349-3BD2AFA8-014E-42BA-B50B-4D940C969075Q36509288-01D12FE5-E16B-4847-B8AE-5761E4180731Q36607211-AE03B0EA-6263-4C3A-9DEE-F19218293450Q36688268-670F5921-6AC1-434C-88E2-76F908EFD9C1Q36822452-DAEC84A6-B465-48AF-9B3A-1EA0866C748FQ37206266-B1B14E0E-E75C-4E11-BF23-7ACE3F859AEFQ37329223-3E517958-B7DF-4EC6-9E34-C8D3E4630E87Q37950838-A50872C2-EDE1-4021-8087-1EE47F9FC835Q39373577-23EA3455-19C9-4DE0-A959-565F342A70CDQ42408495-BC54010B-9809-4E5B-AF3C-D1580A5C3F98Q50043588-601C4197-A8BE-4303-9B86-0A03EB4FD8CEQ58849117-493CB0A9-22EA-485A-BD0B-EBDE515E234B
P2860
Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Recombinant enzyme therapy for ...... an alpha-galactosidase A mRNA.
@ast
Recombinant enzyme therapy for ...... an alpha-galactosidase A mRNA.
@en
type
label
Recombinant enzyme therapy for ...... an alpha-galactosidase A mRNA.
@ast
Recombinant enzyme therapy for ...... an alpha-galactosidase A mRNA.
@en
prefLabel
Recombinant enzyme therapy for ...... an alpha-galactosidase A mRNA.
@ast
Recombinant enzyme therapy for ...... an alpha-galactosidase A mRNA.
@en
P2093
P2860
P356
P1476
Recombinant enzyme therapy for ...... an alpha-galactosidase A mRNA.
@en
P2093
Anneke Strijland
Daniël Blom
Gabor E Linthorst
Johannes M F G Aerts
Wilma G Donker-Koopman
P2860
P356
10.1086/345309
P407
P50
P577
2002-12-06T00:00:00Z